Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Artivion (AORT)

Artivion Q2 revenue rises 11% to $125.8 million; swings to $13.5 million net loss

Mixed Impact 3 of 5 earnings Written later

Artivion reported second-quarter 2026 revenue of $125.8 million, up 11% from a year earlier, and adjusted EBITDA of $26.4 million, up 7%. The company posted a GAAP net loss of $13.5 million ($0.28 per diluted share), compared with net income of $1.3 million a year earlier, and reiterated its full-year 2026 revenue and adjusted EBITDA guidance. For shareholders, revenue grew while GAAP profit fell, and the filing also reports the completed Endospan acquisition and an FDA approval for the AMDS Hybrid Prosthesis.

Key points

  • Q2 2026 revenue was $125.8 million, up 11% on a GAAP basis and 9% in constant currency versus Q2 2025 ($113.0 million).
  • Q2 2026 GAAP net loss was $13.5 million ($0.28 per diluted share), versus net income of $1.3 million ($0.03) in Q2 2025; non-GAAP net income was $6.3 million ($0.13 per share), down from $10.7 million ($0.24).
  • Full-year 2026 guidance was reiterated: revenue of $480 million to $496 million and adjusted EBITDA of $92 million to $99 million.
  • The company completed its acquisition of Endospan Ltd. in May 2026 and announced U.S. FDA PMA approval of the AMDS Hybrid Prosthesis.

The filing

CompanyArtivion (AORT)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:08 PM ET
Accession number0001628280-26-054294

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.